Apremilast tablets have the effect of targeting and regulating systemic inflammation and are mainly used for adult patients with moderate to severe plaque psoriasis. Apremilast reduces the expression of a variety of pro-inflammatory factors and promotes the expression of anti-inflammatory factors, thereby modulating the body’s inflammatory response. It is clinically indicated for the treatment of adult patients with moderate to severe plaque psoriasis who meet the indications for receiving phototherapy or systemic therapy, and has shown good clinical efficacy. Common adverse reactions to this product include nausea, diarrhea, depression, and weight loss. Known hypersensitivity to apremilast or excipients is contraindicated. If a need for medication exists, please obtain a physician’s diagnosis before taking the medication as prescribed.